Contents

**REVIEW**

1694  Nutritional assessment in patients with liver cirrhosis

*Haj Ali S, Abu Sneineh A, Hasweh R*

**MINIREVIEWS**

1704  Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?

*Mandour MO, El-Hassan M, Elkomi RM, Oben JA*

1718  Therapies for non-alcoholic fatty liver disease: A 2022 update

*Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J*

1730  Bile acids as drivers and biomarkers of hepatocellular carcinoma

*Colosimo S, Tomlinson JW*

1739  Approach to persistent ascites after liver transplantation

*Ostojic A, Petrovic I, Silovski H, Kosuta I, Sremac M, Mrzljak A*

**ORIGINAL ARTICLE**

**Case Control Study**

1747  Alcohol intake is associated with a decreased risk of developing primary biliary cholangitis

*French JA, Gow P, Simpson-Yap S, Collins K, Ng J, Angus PW, van der Mei IAF*

**Retrospective Cohort Study**

1757  Positive autoantibodies in living liver donors

*Loh J, Hashimoto K, Kwon CHD, Fujiki M, Modaresi Esfeh J*

**Retrospective Study**

1767  Decrease in liver cancer incidence rates in Bamako, Mali over 28 years of population-based cancer registration (1987-2015)


1778  Modified preoperative score to predict disease-free survival for hepatocellular carcinoma patients with surgical resections


1790  Liver magnetic resonance imaging for evaluation of response to treatment after stereotactic body radiation therapy of hepatocellular carcinoma

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>characteristics, and independent risk factor of hepatocellular</td>
<td></td>
</tr>
<tr>
<td></td>
<td>cancer – nationwide population-based study</td>
<td></td>
</tr>
<tr>
<td>1817</td>
<td>A retrospective study on use of palliative care for patients with</td>
<td>Gupta K, Hans B, Khan A, Sohail SH, Kapuria D, Chang C</td>
</tr>
<tr>
<td></td>
<td>alcohol related end stage liver disease in United States</td>
<td></td>
</tr>
<tr>
<td>1830</td>
<td>Primary hepatic leiomyosarcoma: A case report and literature review</td>
<td>Ahmed H, Bari H, Nisar Sheikh U, Basheer MI</td>
</tr>
<tr>
<td>1840</td>
<td>Analysis of hepatitis C virus-positive organs in liver transplantation.</td>
<td>Legaz I, Muro M</td>
</tr>
</tbody>
</table>
ABOUT COVER
Editorial Board Member of *World Journal of Hepatology*, Mohit Girotra, MD, FASGE, FACC, FACP, Consultant Gastroenterologist and Therapeutic Endoscopist, Digestive Health Institute, Swedish Medical Center, Seattle, WA 98104, United States. girotra.mohit@gmail.com

AIMS AND SCOPE
The primary aim of *World Journal of Hepatology* (*WJH*, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJH* mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING
The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJH* as 0.52. The *WJH*’s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Hepatology is 42/70.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yi-Xuan Cai; Production Department Director: Xiang Li; Editorial Office Director: Xiang Li.

<table>
<thead>
<tr>
<th>NAME OF JOURNAL</th>
<th>INSTRUCTIONS TO AUTHORS</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>World Journal of Hepatology</em></td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/204">https://www.wjgnet.com/bpg/gerinfo/204</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ISSN</th>
<th>GUIDELINES FOR ETHICS DOCUMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISSN 1948-5182 (online)</td>
<td><a href="https://www.wjgnet.com/bpg/gerinfo/287">https://www.wjgnet.com/bpg/gerinfo/287</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LAUNCH DATE</th>
<th>GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>FREQUENCY</th>
<th>PUBLICATION ETHICS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>EDITORS-IN-CHIEF</th>
<th>PUBLICATION MISCONDUCT</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>EDITORIAL BOARD MEMBERS</th>
<th>ARTICLE PROCESSING CHARGE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PUBLICATION DATE</th>
<th>STEPS FOR SUBMITTING MANUSCRIPTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>COPYRIGHT</th>
<th>ONLINE SUBMISSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>© 2022 Baishideng Publishing Group Inc</td>
<td><a href="https://www.f6publishing.com">https://www.f6publishing.com</a></td>
</tr>
</tbody>
</table>
Bile acids as drivers and biomarkers of hepatocellular carcinoma

Santo Colosimo, Jeremy W Tomlinson

Abstract

The prevalence of hepatocellular carcinoma (HCC) is rapidly increasing, driven not least in part by the escalating prevalence of non-alcoholic fatty liver disease. Bile acid (BA) profiles are altered in patients with HCC and there is a developing body of evidence from in vitro human cellular models as well as rodent data suggesting that BA are able to modulate fundamental processes that impact on cellular phenotype predisposing to the development of HCC including senescence, proliferation and epithelial-mesenchymal transition. Changes in BA profiles associated with HCC have the potential to be exploited clinically. Whilst excellent diagnostic and imaging tools are available, their use to screen populations with advanced liver disease at risk of HCC is limited by high cost and low availability. The mainstay for HCC screening among subjects with cirrhosis remains frequent interval ultrasound scanning. Importantly, currently available serum biomarkers add little to diagnostic accuracy. Here, we review the current literature on the use of BA measurements as predictors of HCC incidence in addition to their use as a potential screening method for the early detection of HCC. Whilst these approaches do show early promise, there are limitations including the relatively small cohort sizes, the lack of a standardized approach to BA measurement, and the use of inappropriate control comparator samples.

Key Words: Bile acid; Liver cancer; Screening; Cirrhosis; Serum metabolites; Urine metabolites

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: The rapidly increasing prevalence of hepatocellular carcinoma (HCC) highlights the unmet clinical need to develop and enhance early diagnostic strategies. Evidence from rodent and in vitro models suggests that bile acids may have a crucial role in the pathogenesis of HCC. Changes in circulating bile acid profiles are observed in patients with HCC. Serum and urine bile acid profiles may predict HCC risk and may have potential as a non-invasive screening tool.

INTRODUCTION

The increasing prevalence of hepatocellular carcinoma (HCC) in recent years has focused the need not only to develop better treatment strategies, but also to identify and validate accurate, non-invasive early detection strategies with the aim of improving clinical outcome. In 2018, HCC was ranked as the sixth most common incident cancer and fourth highest for mortality outcome by the World Health Organization[1]. Much of the increase in incidence is driven by the epidemic of non-alcoholic fatty liver disease (NAFLD), which is rapidly becoming the most prevalent etiology for cirrhosis, HCC and liver transplant[2].

Currently, screening strategies for HCC detection are based on regular interval ultrasound scanning (US) (usually 6 moly) while diagnosis is often confirmed by computerized tomography (CT) scan or magnetic resonance imaging (MRI). The performance of US in early detection of HCC is dependent upon both the expertise of the operator and the quality of the equipment[3]. CT scanning is not recommended for surveillance due to radiation exposure and MRI is expensive and not as widely available. Alpha-fetoprotein (AFP) is the most widely available serum biomarker test for HCC. Despite being tested as a diagnostic tool, only two studies have investigated its performance as a stand-alone screening method for early-stage HCC[4,5]. The data are mixed and to some extent conflicting; whilst one study suggested that AFP screening can miss many incident HCCs, the other reported improved early detection, although there was no impact on clinical outcome. Importantly, in both studies, the major underlying chronic liver disease was either hepatitis B virus (HBV) or hepatitis C virus (HCV) infection related cirrhosis. AFP accuracy to detect early-stage HCC remains sub-optimal even when combined with US, increasing the accuracy by only 6%-8%[4,6]. AFP levels may also vary in patients with HBV and HCV-related cirrhosis following flares of viral replication or disease progression with further fluctuations being observed in patients with cirrhosis whenever the underlying liver disease exacerbates[7]. Moreover, early-stage HCCs express AFP in only 10%-20% of cases[8].

Bile acids (BA) include a variety of lipid compounds that are synthesized in hepatocytes, secreted into the biliary tree and stored in the gall bladder. The primary bile acids (cholic (CA) and chenodeoxycholic acid (CDCA)) are dehydroxylated to secondary bile acids by gut microbiota, reabsorbed in the intestine and conjugated in the liver (Figure 1). The amount of BA recirculating within the enterohepatic circulation is constant (approximately 3 g). As little as 0.5 mg of BAs spill over into the systemic circulation and are subsequently excreted into urine. Bile acid composition in serum and urine is thought to be proportional to concentration in the gallbladder.

The biochemical modifications that BAs undergo during this cycle reflect their functions as dietary fat emulsifiers. Importantly however, it is now widely recognized that BAs have a diverse array of functions to regulate cellular metabolic, inflammatory and proliferative phenotypes, mediated through a series of discrete BA receptors.

Farnesoid X receptor (FXR) is a nuclear receptor expressed in hepatocytes and enterocytes and is most potently activated by CDCA. FXR activation within the liver downregulates lipogenesis and enhances lipolysis preventing liver fat accumulation whilst in the intestine, it promotes inflammation and insulin resistance. Takeda G protein-coupled receptor 5 (TGR5) is a bile acid-specific G protein-coupled receptor that activates various intracellular signaling pathways. Pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are BA nuclear receptors involved in the regulation of drug metabolism and BA conjugation[9].

In this review, we will discuss the evidence supporting the role of BAs and their receptors in the pathogenesis of HCC focusing largely on human models. In addition, we discuss the potential utility of BA profiling as a risk stratification and early diagnostic tool in the management of patients at risk of developing HCC.
Bile acids and HCC

Evidence from rodent models
FXR-null mice accumulate BAs and develop spontaneous HCC in approximately 90% of cases\(^\text{[10]}\). In addition, liver-specific FXR-knockout mice also develop spontaneous HCC in 20% of cases whilst intestine-specific FXR-knockout only develop HCC in 5% of cases. The rate of HCC onset increases with diethylnitrosamine (DEN) treatment, a well-recognized driver of the development of HCC, as well as treatment with cholic acid\(^\text{[11]}\). Conversely, in a humanized rodent model of NASH-associated HCC induced by DEN and high fat choline-deficient diet, administration of obeticholic acid (OCA), a synthetic bile acid FXR potent agonist, upregulated p53 and downregulated STAT3, a regulatory pattern that limits apoptosis and cancer promotion\(^\text{[12]}\).

The anti-tumor immune response is also modulated by BA. Increased conversion of primary to secondary bile acids by an altered gut-microbiota has been associated with CXCL16 downregulation in Natural Killer T-cells (NK) and this has been proposed to exert a weaker antitumor immune response\(^\text{[13]}\).

In addition to FXR, other BA receptors have been implicated in the pathogenesis of HCC, although they have been studied in less detail. TGR5 activation may be involved in the anti-tumor immune response. In a tumor-bearing murine model, administration of ursodeoxycholic acid restrained T-reg cell activation working through the TGR5-AMPK-PKA (AMP-kinase, protein kinase A) axis, resulting in carboxyl terminus of Hsc70-interacting protein mediated ubiquitination and subsequent degradation of TGF-beta\(^\text{[14]}\).

To date there are currently no studies that have specifically examined the role of CAR and PXR in the pathogenesis of HCC and this is clearly an area where further research is required. PXR is expressed in the intestine and has been suggested to have a role in the pathogenesis of colon cancer\(^\text{[15]}\). However, the specific pathways maybe different between colon and liver and therefore dedicated studies in HCC models are warranted.

Evidence from rodent studies would therefore suggest that BA accumulation alongside suppression of FXR expression may act synergistically in promoting carcinogenesis. However, it is important to note that there are fundamental differences in BA synthesis and metabolism between rodents and humans (exemplified by the exclusive generation of muricholic acids and their metabolites in rodents) and this may limit the interpretation of rodent derived data.

Evidence from human in vitro models
The data from human in vitro models are complex but do suggest a potential role for BA in HCC pathogenesis. In Huh-7 and Hep3B cell models, physiological doses of OCA and CDCA promote epithelial-mesenchymal transition (EMT) through the expression of TGF-Beta\(^\text{[16]}\). EMT is a process that entails changes in the shape of cells with loss of polarity, cell-cell adhesion, and gain of spindle shape, migratory and invasive potential and may be critical for the malignant transformation of hepatocytes.
Furthermore, in human hepatoma HepG2 cells, CDCA promotes cellular proliferation and reduces sensitivity to the chemotherapeutic agent 5-fluorouracil[17]. These data would suggest that BA may promote HCC development, however, there may also be a dose-dependency of effect. When administered in higher doses, OCA suppresses cell growth and induces cell death[16].

Hepatic stellate cells (HSC) are a subgroup of hepatic cells that account for 10% of the total cell mass of the liver and are fundamental in driving hepatic fibrosis. They maintain a quiescent phenotype in normal liver and transdifferentiate to myofibroblasts after a liver injury. There is evidence to suggest that DCA may indirectly promote hepatocellular carcinogenesis through initiation of HSC senescence. Incubation of HSC with DCA drives inflammation through the release of TGF-beta and IL-8 and both of these cytokines are able to modify the expression of adhesion molecules promoting EMT and subsequent HCC risk[18].

Ursodeoxycholic acid, a secondary BA produced by the gut microbiota causes a dose- and time-dependent increase in HepG2 cell apoptosis by activating the mitochondrial cell death pathway[19]. In addition, taurocholic acid (TCA) has an antiproliferative effect on HepG2 increasing the expression of adhesion molecules and promoting apoptosis, that may inhibit or even reverse EMT[20].

Taken together, all these data would suggest that BAs may play a role in the regulation of cellular phenotype that may predispose to the development of HCC (Figure 1), but the mechanisms are complex and currently poorly understood.

### USING BILE ACID AS A CLINICAL TOOL IN PATIENTS WITH, OR AT RISK OF HCC

Based on the preclinical evidence, it has been proposed that specific patterns of serum and urine BAs concentrations may predict HCC risk or facilitate the early detection of HCC. There are many potential benefits of such approach. Firstly, this may reduce the number of percutaneous liver biopsies needed. Secondly, it may enhance the rate of early diagnosis with the potential to improve clinical outcome.

**Bile acids as predictors of HCC incidence**

Based upon in vitro and preclinical observations, BA profiling has been used as a tool to predict the subsequent development of HCC. Wang et al[21] reported the results of a retrospective study and showed that elevated total serum bile acids (TBA) levels were an independent risk factor for the future development of HCC. After adjusting for liver fibrosis using a non-invasive risk stratification tool (AST to platelet ratio index, APRI) and the presence of ascites, total BA levels were found to be elevated in those patients who later developed HCC on a background of HBV-related cirrhosis.

More recently, a further study has reported an increased risk of developing HCC in cirrhotic patients with increased total BA. In addition, after adjustment for potential confounders, the taurochenodeoxycholic acid/glycochenodeoxycholic acid (TCDCA/GCDCA) and the taurodeoxycholic acid/glycodeoxycholic acid (TDCA/GDCA) ratios were both associated with a higher risk of developing HCC four years later. In contrast, a decrease in the TCA/CDCA ratio was associated with a reduction in the risk of HCC[22].

In a multi-centre, prospective observational cohort study, Stepien et al[23] defined the metabolic perturbations that precede the diagnosis of HCC. Among fourteen metabolites identified in the study, elevated serum levels of glycocholic acid (GCA) and GCDCA were associated with an increased risk of developing HCC. However, it is important to note that in this study, comparison was made against healthy controls matched to patients with HCC at the time of case occurrence. A comparison to patients with established cirrhosis was not made and therefore this limits the interpretation of their findings. However, these results are consistent with those of previously reported studies suggesting that elevated TBA, and specifically primary bile acid levels, are associated with an increased risk of developing HCC.

The mechanisms that underpin these observations remain poorly understood. Detailed studies examining the role of BA conjugation in the development of HCC have not been performed. However, diets high in saturated and milk-derived fats specifically increase serum levels of taurine-conjugated bile acids in rodents[24]. Increased taurine-conjugated bile acids levels may therefore be a surrogate marker providing a reflection of dietary composition that could drive HCC risk through the progression to advanced NAFLD.

**Bile acids and the early detection of HCC**

Current screening strategies for the early detection of HCC in patients with advanced liver disease are heavily reliant on US imaging. However, several studies have tried to use measurements of serum (and in some cases urine) BA profiles as an early detection strategy.

Han et al[25] measured selected BAs (CDCA, GCA and GCDCA) in 3 distinct patient groups: One group with HCC, one group with cirrhosis but not HCC and a third group of healthy controls. In both the HCC and cirrhosis groups, levels of GCDCA and GCA were found to be higher than in healthy controls. CDCA levels were reduced in patients with HCC compared to both patients with cirrhosis and healthy control subjects, suggesting a potential protective effect against tumorigenesis[25]. In the same study, samples of HCC tumor tissue were also analyzed. Levels of all three bile acids were reduced and
it is possible that this may provide an environment which allows HCC to develop by increasing inflammation and disrupting the efficacy of the immune response (Figure 1).

In a retrospective, case-control study that incorporated an analysis of the serum metabolome to identify potential markers for HCC, total BA concentrations were higher in patients with HCC [with and without diabetes mellitus type 2 (T2DM)] compared to patients with T2DM but without HCC and to healthy controls[26].

Several other studies have also confirmed higher levels of specific bile acids (most frequently GCA, but also taurodeoxycholic acid, taurocholate, glycocholate, CDCA and cholic acid) in the serum or plasma of patients with HCC when compared to healthy controls[27-33]. However, there is some variability as to the underlying etiology of chronic liver disease predisposing to HCC in these cohorts and direct comparison of BA profiles amongst these etiologies has not been made. Some of the published data are not entirely consistent and highlight the critical importance of matching, clinically relevant comparator cohorts. GCA and GDCA were found to be significantly decreased in a cohort of patients with HCC when compared to those with cirrhosis, whilst they were increased with respect to healthy volunteers[34]. Another study using samples mainly from patients with HCV and HBV related cirrhosis and HCC has shown that GCA, GCDCA, TCA, and TDCA were decreased in patients with HCC compared to those with cirrhosis[35]. Taken together, these data would seem to suggest that the changes in GCA and GDCA are the most consistent in the majority, although not all, of the published studies and could offer biomarker potential. However, on their own in isolation and without additional biomarkers (or the use of machine learning strategies) they are unlikely to offer sufficient specificity or sensitivity as an early detection test. A summary of findings from all the published studies is presented in Table 1.

Familial intrahepatic cholestasis is a group of rare genetic disorders involving bile acid transport and synthetic defects characterized by BA accumulation in liver parenchyma. Although available data are limited, there is some evidence to suggest, a risk of early onset HCC in these groups of patients[36]. Specific bile acids are found predominantly in fetal life or in rare genetic disorders of bile acid synthesis. 7α-hydroxy-3-oxocholest-4-en-24-oic acid and 3-oxocholest-4,6-dien-24-oic acid are not normally secreted in adults, but have been identified in plasma and urine of patients with cirrhosis and HCC[37,38]. An additional study has also suggested that Delta(4)- and/or allo-bile acids levels in urine are increased in patients with HCC[39]. Other chronic liver conditions are also associated with changes in BA levels that can predispose to malignancy. In cases of primary biliary cholangitis and primary sclerosing cholangitis, BA accumulation enhances necrosis and apoptosis of hepatocytes through mitochondrial damage, membrane disruption and ROS production. The chronic damage with oxidative stress and pro-inflammatory microenvironment can promote carcinogenesis[9].

Rather than focusing on individual BA levels, machine learning algorithms applied to BA profiles have been used successfully to differentiate benign from malignant hepatobiliary strictures[40]. Combining BAs and machine learning has not been applied to the diagnosis of HCC diagnosis but may offer a strategy to improve diagnostic and prognostic performance.

There are important inconsistencies and limitations in the published data that make direct comparisons challenging and limit the interpretation of study results. Most studies used liquid chromatography mass spectrometry to quantify bile acids and their metabolites. However, the methodology is not standardized and therefore results from different laboratories may not be completely reproducible or comparable. Race, age, gender, diet, medication, circadian rhythm are factors that can influence BAs basal concentration. Therefore, BA pool composition rather than absolute BA concentrations should be considered to overcome or adjust for individual differences. Furthermore, since the composition of BA profiles are not consistent, it is difficult to find consensus over the definition of a standard pool[41]. Study designs are also heterogeneous. Some of the reports are case-control studies designed to detect differences in the risk of development of HCC, whilst others are cross-sectional studies or retrospective studies aiming to identify differences in the concentration of specific biomarkers between patients with HCC and subjects at high risk or healthy control participants. Since most cases HCC develops on a background of cirrhosis (of differing aetiologies), it is essential that a biomarker is accurate enough to discriminate patients with disease-specific cirrhosis from those with HCC. Head-to-head comparisons of BAs measurements against the standard screening approaches of US+/-AFP have not been performed. However, these studies would be crucial next step in order to assess the potential clinical advantage of using BA profiles in replacement or addition to US+/-AFP as screening strategy.

**CONCLUSION**

In conclusion, there is a growing body of evidence detailing a role for BAs and their signaling in the pathogenesis of HCC. It is likely that this translates to clinical alterations in BA profiles that have been measured in serum and urine from patients with HCC and those with cirrhosis. What remains uncertain is how these observations may translate to the development of meaningful biomarkers that might help guide clinical management or predict clinical outcome. Adopting a standardized approach to the measurement of BAs, combined with innovative approaches to the analysis and interpretation, perhaps
Table 1 Summary data of clinical studies examining the utility of bile acid profiling in the diagnosis and screening for hepatocellular carcinoma

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Type of Study</th>
<th>Clinical Cohort (No.)</th>
<th>Control Cohort</th>
<th>Underlying Chronic Liver Disease</th>
<th>No. of Subjects (Male)</th>
<th>Samples</th>
<th>Outcome vs Control</th>
<th>Outcome vs Cirrhosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Retrospective</td>
<td>Cirrhosis without HCC (1082)</td>
<td>NA</td>
<td>HBV</td>
<td>2262 (1710)</td>
<td>Serum</td>
<td>Increased TBA</td>
<td>Increased TBA -&gt; risk factor for HCC</td>
</tr>
<tr>
<td>2</td>
<td>Case-Control</td>
<td>HCC (100)</td>
<td>Healthy Match (age, gender, dialect group)</td>
<td>MAFLD/ Cryptogenic</td>
<td>200 (150)</td>
<td>Serum</td>
<td>Increased TBA and CPBA</td>
<td>Increased TBA and CPBA -&gt; risk factor for HCC</td>
</tr>
<tr>
<td>3</td>
<td>Case-Control</td>
<td>Cirrhosis without HCC (129)</td>
<td>Healthy Match (age, sex, centre etc.)</td>
<td>Any</td>
<td>258 (176)</td>
<td>Serum</td>
<td>Increased TBA and CPBA -&gt; risk factor vs healthy control</td>
<td>Increased TBA and CPBA</td>
</tr>
<tr>
<td>4</td>
<td>Cross-Sectional</td>
<td>HCC (30)</td>
<td>Healthy (30)</td>
<td>Cirrhosis (30)</td>
<td>HBV</td>
<td>90 (58)</td>
<td>Serum</td>
<td>GCDCA reduced in HCC</td>
</tr>
<tr>
<td>5</td>
<td>Cross-Sectional</td>
<td>HCC (16)</td>
<td>Healthy (27)</td>
<td>T2DM (27)</td>
<td>NAFLD/ Cryptogenic</td>
<td>80 (50)</td>
<td>Serum</td>
<td>Increased TBA in HCC +/- T2DM vs T2DM and healthy</td>
</tr>
<tr>
<td>6</td>
<td>Case Control</td>
<td>HCC (121)</td>
<td>HBV positive non-cirrhotic</td>
<td>HBV</td>
<td>242 (242)</td>
<td>Serum</td>
<td>Increased TDCA, CA, TC, GC</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Case Control</td>
<td>HCC (14)</td>
<td>Healthy</td>
<td>NA</td>
<td>28</td>
<td>Plasma/ Urine</td>
<td>Urine and Plasma GCA 3-24 times increased in HCC</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Cross-Sectional</td>
<td>HCC (516)</td>
<td>Cirrhosis Healthy</td>
<td>NA</td>
<td>1448 (1076)</td>
<td>Serum</td>
<td>GCA and Phe-Trp validated for HCC prevention and detection</td>
<td>GCA (increased) and Phe-Trp validated for HCC prevention and detection</td>
</tr>
<tr>
<td>9</td>
<td>Case Control</td>
<td>HCC (11)</td>
<td>Healthy</td>
<td>NASH</td>
<td>79</td>
<td>Serum</td>
<td>Increased PBA in NASH- HCC vs NASH</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Prospective</td>
<td>HCC (78)</td>
<td>Cirrhosis</td>
<td>HCV</td>
<td>262 (165)</td>
<td>Serum</td>
<td>Metabolites of PBA are downregulated in HCC (GCDCA, GCA)</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Cross-Sectional</td>
<td>HCC (40)</td>
<td>Cirrhosis</td>
<td>HCV</td>
<td>89 (64)</td>
<td>Serum</td>
<td>GCA, GDCA increased</td>
<td>GCA, GDCA reduced</td>
</tr>
<tr>
<td>12</td>
<td>Cross-sectional</td>
<td>PSC (20), CCA (20), HCC (20)</td>
<td>Healthy</td>
<td>NA</td>
<td>80 (55)</td>
<td>Serum</td>
<td>GCA elevated in HCC vs control</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Case Control</td>
<td>HCC (30)</td>
<td>Healthy (6), Cirrhosis (7), AML (22)</td>
<td>NA</td>
<td>53 (35)</td>
<td>Plasma</td>
<td>Fetal BAs increased in HCC vs AML</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Cross-sectional</td>
<td>HCC (27)</td>
<td>Cirrhosis (49), Viral Hepatitis (11), Liver Metastasis (19), Healthy (26)</td>
<td>NA</td>
<td>132 (91)</td>
<td>Urine</td>
<td>Increased Delta(4)- and/or allo-bile acids in urine</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Cross-sectional</td>
<td>CCA (25), HCC (75)</td>
<td>Healthy (21)</td>
<td>NA</td>
<td>121 (121)</td>
<td>Serum</td>
<td>Glyco-BA:Tauro-BA increased in</td>
<td></td>
</tr>
</tbody>
</table>

WJH | https://www.wjgnet.com | 1735 | September 27, 2022 | Volume 14 | Issue 9 |
including the use of artificial intelligence and machine learning, may facilitate their meaningful clinical use to enhance patient care.

**FOOTNOTES**

**Author contributions:** All authors have read and approve the final manuscript.

**Conflict-of-interest statement:** All the Authors have no conflict of interest related to the manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** United Kingdom

**ORCID number:** Santo Colosimo 0000-0002-1724-498X; Jeremy W Tomlinson 0000-0002-3170-8533.

**S-Editor:** Wang LL

**L-Editor:** A

**P-Editor:** Wang LL

**REFERENCES**


9. Sun L, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. *Nat


16 Kainuma M, Takada I, Makishima M, Sano K. Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells. *Int J Mol Sci* 2018; 19 [PMID: 29588417]


